21:28 , Jul 19, 2019 |  BC Extra  |  Preclinical News

July 19 Preclinical Quick Takes: Samumed's Alzheimer's candidate; plus a CRISPR RNA editing tool, new targets for fibrosis and pain

Samumed's Alzheimer's candidate reduces tau pathology, inflammation  Samumed LLC (San Diego, Calif.) reported in an Aging Cell paper that SM07883 reduced tau phosphorylation, pathological tau aggregates, neuroinflammation, weight loss and mortality in a mouse model...
05:29 , Feb 8, 2019 |  BC Week In Review  |  Clinical News

Samumed unveils MOA for Wnt inhibitor OA therapy

Samumed LLC (San Diego, Calif.) reported preclinical data showing that its small molecule Wnt pathway inhibitor osteoarthritis therapy, SM04690, functions through CLK-2 and DYRK1A inhibition. Data were presented at the Orthopaedic Research Society meeting in...
23:19 , Dec 21, 2018 |  BC Extra  |  Preclinical News

Combined inhibition of DYRK1A, TGFβ increases β cell proliferation

Researchers from the Icahn School of Medicine at Mount Sinai and colleagues showed that dual inhibition of DYRK1A and transforming growth factor β (TGFβ) synergistically increased human β cell proliferation, suggesting the combination could be...
17:21 , Aug 30, 2018 |  BC Innovations  |  Tools & Techniques

Master of autism

The discovery of a master regulator of autism risk genes has yielded the first mouse model of the form of the condition that accounts for about 90% of patients, and could spark a new way...
19:34 , May 17, 2018 |  BC Innovations  |  Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
20:27 , Nov 16, 2017 |  BC Innovations  |  Translation in Brief

Lighting up the DYRK

Kyoto University researchers have described a DYRK1A inhibitor that could treat neuronal deficits in Down syndrome with fewer side effects than other inhibitors of the kinase -- but neurology company NeuroNascent Inc. suggests the safety...
19:22 , Sep 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Cognitive dysfunction In vitro and mouse studies identified an indazole-based inhibitor of DYRK1A that could help treat Down syndrome in fetuses. Screening of a small molecule library in mouse neural stem cells identified a...
08:00 , Jan 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A); glycogen synthase kinase 3β (GSK3β)

Endocrine/metabolic disease INDICATION: Diabetes In vitro, rodent and human tissue studies suggest dual inhibitors of GSK3β and DYRK1A could increase β cell mass to help treat diabetes. Chemical synthesis of aminopyrazine analogs and testing in...
07:00 , Jul 20, 2015 |  BioCentury  |  Emerging Company Profile

Shot in the DYRK

Felicitex Therapeutics Inc. is discovering and developing small molecule cancer agents that target cell quiescence, a mechanism cancer cells can use to resist treatment. Cell quiescence is a reversible phenomenon where cells stop dividing and...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Company News

Diaxonhit, Felicitex Therapeutics deal

Diaxonhit granted Felicitex exclusive, worldwide rights to develop and commercialize preclinical small molecule compounds targeting dual-specificity tyrosine-(Y)-phosphorylation regulated kinase (DYRK) to treat pancreatic cancer. Diaxonhit received an upfront payment and is eligible for development milestones...